adefovir dipivoxil + cyclosporine

ADEFOVIR DIPIVOXIL + CYCLOSPORINE** is a combination of two pharmaceutical agents: **adefovir dipivoxil**, an oral prodrug of adefovir, and **cyclosporine**, a potent immunomodulatory agent. - **Adefovir dipivoxil** is converted in cells to adefovir diphosphate, an acyclic nucleotide phosphonate analogue of adenosine monophosphate, which inhibits hepatitis B virus (HBV) DNA polymerase (reverse transcriptase) by competing with deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA[2][4][1]. - **Cyclosporine** suppresses immune function primarily by inhibition of T-cell activation via blocking the transcription of cytokines, specifically interleukin 2, through binding to cyclophilin[6]. This mechanism is leveraged clinically for immunosuppression in transplant patients and several autoimmune diseases. - The combination may be used in clinical settings where immunosuppression overlaps with chronic HBV infection, but is associated with increased risk of nephrotoxicity due to the additive renal effects of both agents, requiring careful monitoring[3][1]. - There is no proprietary, brand, or unique product name specific for this combination.

Other names

adefovir dipivoxil + cyclosporine